MAGEA11 and cancer: During the follow-up period, cancer-related death and the other cause of death were documented in 40 (78.4%) and 11 patients (21.6%) for MAGE-A6 expression and 42 (79.2%) and 11 patients (20.8%) for MAGE-A11, respectively.